VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
187.10
+2.16 (+1.17%)
As of 2:53PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close184.94
Open186.24
Bid186.95 x 1100
Ask187.10 x 800
Day's Range185.97 - 187.71
52 Week Range151.80 - 195.81
Volume553,717
Avg. Volume1,201,631
Market Cap48.091B
Beta (3Y Monthly)1.09
PE Ratio (TTM)21.96
EPS (TTM)8.52
Earnings DateOct 22, 2019 - Oct 28, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est213.05
Trade prices are not sourced from all markets
  • Top Research Reports: Amazon, Caterpillar, Vertex & More
    Zacks

    Top Research Reports: Amazon, Caterpillar, Vertex & More

    Top Research Reports: Amazon, Caterpillar, Vertex & More

  • Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
    Zacks

    Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

    Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

  • Mergers & Acquisitions Take Center Stage in Biotech Industry
    Zacks

    Mergers & Acquisitions Take Center Stage in Biotech Industry

    Mergers & Acquisitions Take Center Stage in Biotech Industry

  • Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals
    Motley Fool

    Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals

    Two great biotechs focused on rare diseases. But one of them gets the nod as the better pick.

  • The 10 Largest-Cap Growth Stocks
    Motley Fool

    The 10 Largest-Cap Growth Stocks

    Investors know it's not easy to find companies already worth tens of billions that can still expand their revenues rapidly. But these giants show it's not impossible.

  • Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up
    Zacks

    Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up

    Puma Biotech (PBYI) incurs wider loss in Q2. Sales of Nerlynx improve from first-quarter levels. Stock rises 23%.

  • Perrigo (PRGO) Beats on Q2 Earnings and Sales, Stock Up
    Zacks

    Perrigo (PRGO) Beats on Q2 Earnings and Sales, Stock Up

    Perrigo (PRGO) reports encouraging second-quarter 2019 results. The Rx segment recovers on strong new product sales.

  • Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss
    Zacks

    Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss

    Celldex (CLDX) reports mixed second-quarter results. Revenues fall on reduced collaboration and contract revenues.

  • Is Vertex (VRTX) a Great Growth Stock?
    Zacks

    Is Vertex (VRTX) a Great Growth Stock?

    If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Vertex (VRTX).

  • TipRanks

    3 ‘Strong Buy’ Healthcare Stocks Insiders Are Buying Now

    If you are looking for fresh investing inspiration, it's worth keeping a close eye on the latest insider activity. That's particularly the case when it comes to insider buy transactions i.e. purchases by company executives or owners. A Harvard study revealed the following: "We find that insider purchases earn abnormal returns of more than 6% per year, and insider sales do not earn significant abnormal returns." As a result the authors conclude that insider buyers 'have a good feel for near-term developments within their firm.'Indeed, if a corporate insider- who arguably has the most in-depth knowledge about their company- decides to reach into their own pocket to buy shares, it is a strong indicator that they see the stock as undervalued at current levels.Here we focus on informative transactions rather than uninformative transactions (ie expiring options) and transactions that occurred in the healthcare sector specifically. As you will all three stocks below also boast a Strong Buy Street consensus, based on analyst ratings published over the last three months. Let's take a closer look now: Align Tech (ALGN)Align Technology has made a big name for itself in the world of orthodontics. The company has revolutionized the use of metal braces with its transparent Invisalign teeth aligner system. According to Align, over 7.2 million people including over 1.7 million teens have benefited from Invisalign. That makes the company the clear market leader in its field. The company faced a wave of insider sell transactions two and three months ago. However, the tide appears to be turning. In the last couple of days, President, CEO and director Joseph Hogan picked up $998 worth of ALGN stock. He now has a total Align holding valued at approximately $31.4 million. What’s more, this is an insider with a relatively strong track record on his Align transactions. He bought shares back in February 2018 at $252; sold at $350 in August of the same year; and is now buying again with the stock back down at $188.Raj Pudipeddi is chief marketing officer of ALGN. He has also just made his first transaction- buying $206,000 worth of shares on August 6.In fact Piper Jaffray analyst Matt O'Brien highlights the CEO transaction, as well as Align entering into an accelerated $200 million stock repurchase plan as evidence of management’s confidence in the business over both the intermediate and long term. This Top 100 analyst believes Align can outperform rivals, telling investors that the company "has much better products that will win in the marketplace." As a result O’Brien reiterated his buy rating and $240 price target.Credit Suisse’s Erin Wright is even more optimistic. She has a Street high price target of $320. “While concerns over competition, DTC concepts, and ASPs will remain overhangs, we view there is room for several players in a highly underpenetrated clear aligner market. ALGN is well ahead in terms of innovation, and we await further traction in recently launched products” says the analyst. While the analyst consensus shows Align as a cautiously optimistic Moderate Buy, if we switch to only the best-performing analysts then the consensus shifts to a more bullish Strong Buy. Indeed out of 7 top-rated analysts covering the stock, 6 rate ALGN a buy. And their $269 average price target suggests considerable upside potential of 46%. Vertex Pharma (VRTX)This groundbreaking biotech specializes in cystic fibrosis (CF) therapies. This is a rare, life-shortening genetic disease affecting approximately 75,000 people in North America, Europe and Australia.Vertex is making important progress in the treatment of the disease. It just submitted a New Drug Application (NDA) to the US FDA for a Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor. “The submission of the NDA is a major step toward our goal of bringing this medicine to the largest remaining group of people with CF that still do not have an approved Vertex medicine, as well as toward providing significantly enhanced benefits to patients with two F508del mutations” Vertex’s chief medical officer wrote following the submission on July 22.And now two insiders have arguably demonstrated their confidence in the application by making large stock purchases. Michael Parini, an exec VP and the company’s chief legal and admin officer, snapped up $201,592 worth of stock this week, bringing his total holding to $6.2 million. Meanwhile chief commercial officer Stuart Arbuckle upped his holding by $330,578 to over $5.7 million. And these insiders aren’t the only financial experts demonstrating bullish sentiment right now. The stock shows a ‘Strong Buy’ Street consensus with 10 out of 12 analysts rating VRTX a buy. That’s with an average price target of $217 (25% upside potential). “Vertex put up another very strong quarter (top- / bottom-line beats) with all three cystic fibrosis assets topping expectations” enthused JP Morgan analyst Cory Kasimov on August 1. “With strong ongoing execution on the CF front, focus continues to turn to the pipeline for the next potential leg of the story. We are finding current stock levels increasingly attractive as 2020 is setting up to be a year of major growth potential both in terms of financial (via early 2020 triple approval) and clinical performance” the analyst told investors. Avrobio (AVRO)Biotech Avrobio is developing lentiviral-based gene therapies that it believes can transform patients' lives in a single dose. Its most advanced pipeline drug is for Fabry disease- a rare inherited disorder that results from the buildup of a particular type of fat in the body's cells. The market opportunity is significant: worldwide sales of roughly $4 billion in 2017 for lysosomal storage diseases (LSDs), which analysts see as Avrobio’s total addressable market.In the last two weeks, both a director and one of the company’s owners have each snapped up a further $15 million of Avrobio stock. That brings director Bruce Booth’s total holding in the company up to a whopping $100 million. Interestingly this is by far his biggest holding, but he does have million-dollar positions in three more biotech stocks: Magenta Therapeutics; Unum Therapeutics; and Miragen Therapeutics. Luckily for Booth, Avrobio has a very bullish outlook from the Street right now. Although only three analysts have published recent AVRO ratings- all three rate the stock a buy. Plus their $34 average price target indicates upside potential of 90%. Top Mizuho Securities analyst Difei Yang reiterated her buy rating and $28 price target on July 16. “We believe AVROBIO's robust clinical development program has potential to demonstrate significant clinical benefits in Fabry patients and ultimately position the company's gene therapy as a first-line treatment” she cheered. Yang made the call after AVRO released positive new trial data showing sustained efficacy and a promising safety profile. Most encouragingly, 3/5 patients treated in the Phase 1 trial have discontinued standard of care enzyme replacement therapy (ERT) so far, added the analyst. Looking forward, additional Fabry updates could be available in late 2019/early 2020 although no specific timeline has yet been provided by management. Discover stocks with positive insider sentiment here

  • Sarepta moves beyond rare disease, eyes multiple sclerosis gene therapy
    American City Business Journals

    Sarepta moves beyond rare disease, eyes multiple sclerosis gene therapy

    After years as a rare disease drugmaker, Sarepta Therapeutics Inc. is expanding into a neurological disease that affects millions of people worldwide and has been dominated for years by its Cambridge neighbor, Biogen Inc.

  • Thomson Reuters StreetEvents

    Edited Transcript of VRTX earnings conference call or presentation 31-Jul-19 8:30pm GMT

    Q2 2019 Vertex Pharmaceuticals Inc Earnings Call

  • GuruFocus.com

    Vertex Pharmaceuticals Inc (VRTX) EVPChief Commercial Officer Stuart A Arbuckle Sold $657,132 ...

    EVP\Chief Commercial Officer of Vertex Pharmaceuticals Inc (30-Year Financial, Insider Trades) Stuart A Arbuckle (insider trades) sold 3,708 shares of VRTX on 08/05/2019 at an average price of $177.22 a share. Continue reading...

  • Vertex Has "Significant Financial Firepower"
    Motley Fool

    Vertex Has "Significant Financial Firepower"

    A dominant cystic fibrosis franchise drives cash flow.

  • Looking For Growth? Take A Look At These Biotechnology Stocks
    Investor's Business Daily

    Looking For Growth? Take A Look At These Biotechnology Stocks

    The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.

  • Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?

    Is (VRTX) Outperforming Other Medical Stocks This Year?

  • Will This Asteroid Heading Toward Vertex Pharmaceuticals Make Impact?
    Motley Fool

    Will This Asteroid Heading Toward Vertex Pharmaceuticals Make Impact?

    Find out how concerned Vertex investors should be about a potential new cystic fibrosis treatment.

  • Top Biotech Stocks for February 2019
    Investopedia

    Top Biotech Stocks for February 2019

    Biotech a thrilling industry for investors, and one with tremendous opportunity for gains, as shown in early 2019, but it is notably risky for investors, too.

  • Barrons.com

    Vertex Pharmaceuticals Stock Soared on a Strong Earnings Report

    The results, released on Wednesday afternoon, helped to clarify how the company will maintain its revenues after its patents expire for the cystic-fibrosis drugs it now sells.

  • US Stocks Deep in the Red on Thursday
    GuruFocus.com

    US Stocks Deep in the Red on Thursday

    Cigna slides despite strong 2nd-quarter results Continue reading...

  • Vertex Pharmaceuticals Raises Guidance, Shares Follow
    Market Realist

    Vertex Pharmaceuticals Raises Guidance, Shares Follow

    Yesterday, Vertex Pharmaceuticals reported its second-quarter results after the market closed. Today, it was up 1.73% in the premarket session.

  • Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View
    Zacks

    Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View

    Vertex (VRTX) beats on earnings and sales in second-quarter 2019. The company lifts its full-year revenue guidance, led by a solid CF products' performance, especially Symdeko.

  • Vertex Pharmaceuticals Inc (VRTX) Q2 2019 Earnings Call Transcript
    Motley Fool

    Vertex Pharmaceuticals Inc (VRTX) Q2 2019 Earnings Call Transcript

    VRTX earnings call for the period ending June 30, 2019.

  • Proteostasis (PTI) to Post Q2 Earnings: What's in Store?
    Zacks

    Proteostasis (PTI) to Post Q2 Earnings: What's in Store?

    Investors will focus on the cystic fibrosis studies, when Proteostasis (PTI) reports second-quarter 2019 earnings.

  • Vertex Pharmaceuticals (VRTX) Tops Q2 Earnings and Revenue Estimates
    Zacks

    Vertex Pharmaceuticals (VRTX) Tops Q2 Earnings and Revenue Estimates

    Vertex (VRTX) delivered earnings and revenue surprises of 22.33% and 6.52%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?